Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 18, 2022

SELL
$4.75 - $7.5 $1.42 Million - $2.24 Million
-299,200 Closed
0 $0
Q3 2021

Nov 09, 2021

BUY
$5.02 - $6.59 $1.5 Million - $1.97 Million
299,200 New
299,200 $1.7 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track M&G Investment Management LTD Portfolio

Follow M&G Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&G Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on M&G Investment Management LTD with notifications on news.